Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03818685
Title Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03)
Acronym BreastImmune03
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Centre Leon Berard
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Institut de Cancérologie de l'Ouest Angers 49055 France Details
Institut Sainte Catherine Avignon France Details
CHRU Besançon Besançon France Details
Centre Francois Baclesse Caen France Details
Centre d'Oncologie Radiothérapie 37 Chambray-lès-Tours 37170 France Details
Hopital Prive Jean Mermoz Lyon 69008 France Details
Centre Léon Bérard Lyon 69373 France Details
Clinique de la Sauvegarde Lyon France Details
Institut Paoli Calmettes Marseille 13273 France Details
Centre Antoine Lacassagne Nice 06189 France Details
Institut Curie Paris 75005 France Details
GH Pitié-Salpêtrière-Charles Foix Paris 75013 France Details
Institut Jean Godinot Reims 51056 France Details
Institut Curie Saint Cloud 92201 France Details
Institut de Cancérologie de l'Ouest Saint-Herblain 44805 France Details
Centre Paul Strauss Strasbourg 67065 France Details
Hôpital Drôme Ardèche Valence 26000 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field